Stocks and Investing Stocks and Investing
Tue, March 22, 2022
Mon, March 21, 2022
Sun, March 20, 2022
Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022

Vamil Divan Maintained (XERS) at Strong Buy with Decreased Target to $6 on, Mar 16th, 2022


Published on 2024-10-27 20:06:06 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of Mizuho, Maintained "Xeris Biopharma Holdings, Inc." (XERS) at Strong Buy with Decreased Target from $8 to $6 on, Mar 16th, 2022.

Vamil has made no other calls on XERS in the last 4 months.



There are 2 other peers that have a rating on XERS. Out of the 2 peers that are also analyzing XERS, 0 agree with Vamil's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Vamil


  • Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $6 on, Wednesday, February 16th, 2022
  • Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $5.4 on, Friday, December 31st, 2021